Is it safe to co‑administer Lyrica (pregabalin) with Eliquis (apixaban), and what dosing and monitoring considerations are recommended?

Co-Administration of Lyrica (Pregabalin) and Eliquis (Apixaban)

Yes, it is safe to co-administer Lyrica (pregabalin) with Eliquis (apixaban) without dose adjustment, as there are no clinically significant pharmacokinetic or pharmacodynamic interactions between these medications.

Pharmacological Basis for Safety

Pregabalin and apixaban have fundamentally different metabolic pathways that do not overlap:

• Pregabalin undergoes minimal metabolism (<2%), is not protein-bound, and is excreted virtually unchanged by the kidneys. It does not interact with cytochrome P450 enzymes, P-glycoprotein (P-gp), or any hepatic metabolic pathways 1.

• Apixaban is metabolized primarily via CYP3A4 (with some CYP3A5 involvement) and is a substrate of P-glycoprotein. It undergoes 27% renal excretion with the remainder eliminated through biliary and intestinal routes 2.

Since pregabalin does not induce or inhibit CYP3A4, P-gp, or any other drug-metabolizing enzymes 1, it cannot alter apixaban exposure. The recent comprehensive study by 3 specifically evaluated pregabalin's effect on factor Xa inhibitors including apixaban and found no effect on the pharmacokinetics of any oral factor Xa inhibitor, confirming the absence of interaction.

Key Monitoring Considerations

Renal Function Assessment

Both medications require renal dose adjustment, making kidney function the primary monitoring parameter:

For Apixaban 4, 5:

• Standard dose: 5 mg twice daily
• Reduce to 2.5 mg twice daily if patient has ANY 2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL
• Use with caution if CrCl 25-30 mL/min; avoid if CrCl <25 mL/min

For Pregabalin 6, 1:

• Start low (25-50 mg at night) in older adults
• Dose adjustment required for renal insufficiency
• CrCl 30-60 mL/min: reduce dose by 25-50%
• CrCl 15-30 mL/min: reduce dose by 50-75%
• CrCl <15 mL/min: reduce dose by 75% or use alternative

Bleeding Risk Considerations

While pregabalin does not increase bleeding risk directly, monitor for:

• Additive sedation effects: Pregabalin commonly causes somnolence and dizziness 6, 7, which may increase fall risk in patients on anticoagulation
• Concomitant antiplatelet agents: The FDA label explicitly warns that combining apixaban with antiplatelet agents (aspirin, NSAIDs) significantly increases bleeding risk 2. In ARISTOTLE, aspirin co-administration increased bleeding from 1.8% to 3.4% per year
• Peripheral edema: Pregabalin can cause dose-related peripheral edema 7, which should not be confused with bleeding-related complications

Practical Dosing Algorithm

1. Assess baseline renal function using Cockcroft-Gault equation
2. Dose apixaban based on indication and renal/clinical criteria (see above)
3. Dose pregabalin starting at 25-50 mg nightly, titrating weekly based on tolerability
4. Avoid combining apixaban with NSAIDs or antiplatelet agents unless absolutely necessary 2
5. Reassess renal function at least annually, or more frequently if CrCl <60 mL/min 4, 5

Common Pitfalls to Avoid

Do not assume drug interaction based on concurrent use: The absence of metabolic pathway overlap means these drugs can be safely combined 1, 3.

Do not overlook fall risk: Pregabalin's CNS effects (somnolence, dizziness, cognitive dysfunction) are particularly problematic in older adults 6 who are also at higher bleeding risk from falls while anticoagulated.

Do not use strong CYP3A4/P-gp inhibitors with apixaban without dose adjustment: Drugs like ketoconazole, itraconazole, or ritonavir require 50% apixaban dose reduction 2. Pregabalin does not fall into this category.

Do not forget that clarithromycin is an exception: Although a combined P-gp and strong CYP3A4 inhibitor, clarithromycin does not require apixaban dose adjustment 2.